Resources from the same session
Are the addition of these new targets really changing patient outcomes globally?
Presenter: Jürgen Wolf
Session: Are large NGS panels really changing patient outcomes?
Resources:
Slides
Webcast
Designing a pragmatic strategy for adequately genotyping advanced NSCLC
Presenter: Myung-Ju Ahn
Session: Are large NGS panels really changing patient outcomes?
Resources:
Slides
Webcast
Immunotherapy biomarkers: What should we be prepared to assess beyond PDL1?
Presenter: Caicun Zhou
Session: Are large NGS panels really changing patient outcomes?
Resources:
Slides
Webcast
LIVE Q&A
Presenter: Myung-Ju Ahn
Session: Are large NGS panels really changing patient outcomes?
Resources:
Webcast